title: Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus.
abstract: Emmprin (extracellular matrix metalloproteinase inducer) is a multifunctional glycoprotein expressed by cancer cells and stromal cells in the tumor microenvironment. Through both direct effects within tumor cells and promotion of tumor-stroma interactions, emmprin induces tumor cell invasiveness and regional angiogenesis. The Kaposi's sarcoma-associated herpesvirus (KSHV) is a common etiology for cancers arising in the setting of immune suppression, including Kaposi's sarcoma and primary effusion lymphoma. However, whether emmprin expression and function are regulated by KSHV or other oncogenic viruses in the tumor microenvironment to promote viral cancer pathogenesis remains unknown. Fibroblasts and endothelial cells support latent KSHV infection and represent cellular components of Kaposi's sarcoma lesions. Therefore, we used primary human fibroblasts and endothelial cells to determine whether KSHV itself regulates emmprin expression, and whether KSHV-emmprin interactions mediate cell invasiveness. We found that KSHV promotes fibroblast and endothelial cell invasiveness following de novo infection through the upregulation of emmprin, and that this effect is mediated by the KSHV-encoded latency-associated nuclear antigen. We also found that emmprin promotes invasiveness, as well as colony formation, by primary effusion lymphoma cells derived from human tumors. Collectively, these data implicate KSHV activation of emmprin as an important mechanism for cancer progression and support the potential utility of targeting emmprin as a novel therapeutic approach for KSHV-associated tumors.
authors.affiliation: Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Qin
authors.forename: Lu
authors.initials: L
authors.lastname: Dai
authors.forename: Mark G
authors.initials: MG
authors.lastname: Slomiany
authors.forename: Bryan P
authors.initials: BP
authors.lastname: Toole
authors.forename: Chris
authors.initials: C
authors.lastname: Parsons
mesh_terms: D000956:Antigens, Viral / Q000235:genetics / Q000378:metabolism; D051926:Basigin / Q000378:metabolism*; D015153:Blotting, Western; D002448:Cell Adhesion; D002465:Cell Movement; D049109:Cell Proliferation; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D003588:Cytopathogenic Effect, Viral; D004730:Endothelium, Vascular / Q000473:pathology; D005347:Fibroblasts / Q000473:pathology; D005455:Fluorescent Antibody Technique; D019288:Herpesvirus 8, Human / Q000472:pathogenicity*; D006801:Humans; D054685:Lymphoma, Primary Effusion / Q000378:metabolism / Q000821:virology*; D009361:Neoplasm Invasiveness; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012514:Sarcoma, Kaposi / Q000378:metabolism / Q000473:pathology / Q000821:virology*; D017735:Virus Latency
chemical_list: D000956:Antigens, Viral; D009687:Nuclear Proteins; D012333:RNA, Messenger; C109540:latency-associated nuclear antigen; D051926:Basigin
references.citation: J Infect Dis. 2005 Mar 1;191(5):755-60
references.pmid: 15688292
references.citation: Drug Resist Updat. 2008 Jun;11(3):110-21
references.pmid: 18490190
references.citation: PLoS Pathog. 2010 Jan 29;6(1):e1000742
references.pmid: 20126446
references.citation: Trends Microbiol. 1996 Nov;4(11):419
references.pmid: 8950809
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51
references.pmid: 10200299
references.citation: Mol Biol Cell. 2004 Sep;15(9):4043-50
references.pmid: 15201341
references.citation: J Virol. 2009 Jan;83(2):622-32
references.pmid: 18971265
references.citation: J Biol Chem. 2003 Jul 11;278(28):25285-8
references.pmid: 12738783
references.citation: J Clin Invest. 2006 Jul;116(7):1963-73
references.pmid: 16794734
references.citation: Thromb Haemost. 2005 Feb;93(2):199-204
references.pmid: 15711733
references.citation: J Virol. 2007 Jul;81(13):7001-10
references.pmid: 17442715
references.citation: J Virol. 2003 Jul;77(14):7978-90
references.pmid: 12829837
references.citation: Cancer Res. 2010 Jan 1;70(1):30-5
references.pmid: 20048070
references.citation: Am J Pathol. 2002 Feb;160(2):641-54
references.pmid: 11839585
references.citation: Science. 1994 Dec 16;266(5192):1865-9
references.pmid: 7997879
references.citation: Science. 2006 Feb 10;311(5762):856-61
references.pmid: 16469929
references.citation: J Virol. 2001 Jan;75(1):458-68
references.pmid: 11119614
references.citation: Cancer Res. 2008 Sep 1;68(17):6963-8
references.pmid: 18757410
references.citation: N Engl J Med. 1995 May 4;332(18):1186-91
references.pmid: 7700311
references.citation: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6360-5
references.pmid: 11353871